Precision Care for Depression

Recruiting in Palo Alto (17 mi)

Overseen by Andrew Krystal, MD, MS

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 4

Waitlist Available

Sponsor: University of California, San Francisco

No Placebo Group

Prior Safety Data

Trial Summary

What is the purpose of this trial?

This study aims to assess whether phenotyping-guided intervention selection is superior to intervention selection without phenotyping guidance (i.e., routine clinician and patient judgment regarding treatment selection) for depression.

Eligibility Criteria

This trial is for individuals with major depressive disorder who are seeking new treatment options. Participants should be diagnosed with depression and willing to try different therapies such as mindfulness, medication, or standard care.

Inclusion Criteria

Participant is able to provide informed consent

I speak English.

I am 18 years old or older.

Exclusion Criteria

Significant risk of suicidal or violent behavior as determined by clinical judgement

Unstable or untreated medical or psychiatric condition based on clinical assessment by investigator(s)

Pregnant or breastfeeding or planning to become pregnant during the study

Treatment Details

Interventions

• Care as usual (CAU) plan (Other)
• CGT (Behavioral Intervention)
• MBSST (Behavioral Intervention)
• Methylphenidate (Drug)
• Phenelzine (Drug)
• Pramipexole (Drug)

Trial Overview The study tests if choosing treatments based on individual characteristics (phenotyping) is better than usual selection methods for depression. Therapies include Mindfulness-based Stress Sensitivity Therapy, medications like Pramipexole and Phenelzine, and standard care.

Participant Groups

Group I: Stress sensitivity: PSI Experimental Treatment 1 Intervention

Group II: Grief: PSI Experimental Treatment 1 Intervention

Group III: Cognitive deficits: PSI Experimental Treatment 1 Intervention

Group IV: Anxious distress: PSI Experimental Treatment 1 Intervention

Group V: Anhedonia phenotype: PSI Experimental Treatment 1 Intervention

Group VI: Stress sensitivity: CAU Active Control 1 Intervention

Group VII: Grief: CAU Active Control 1 Intervention

Group VIII: Cognitive deficits: CAU Active Control 1 Intervention

Group IX: Anxious distress: CAU Active Control 1 Intervention

Group X: Anhedonia phenotype: CAU Active Control 1 Intervention

Find a Clinic Near You

Research Locations Nearby Select from list below to view details:

Nancy Friend Pritzker Psychiatry Building, University of California, San Francisco San Francisco, CA

Who Is Running the Clinical Trial?

University of California, San Francisco Lead Sponsor

References